Rare disease trials usually mean a small, geographically scattered patient population, a heavy reliance on natural history or registry data, and outcomes that are often reported by a caregiver rather than the patient. Capture's EDC, ePRO and registry-friendly data model fit that pattern without a rare-disease-specific price tag.
Free sandbox · No credit card · 21 CFR Part 11 aligned
Patient-reported
Participant, own phone
Observer-reported
Caregiver
Clinician-reported
Site staff, clinic tablet
Performance outcome
Site-run test, e.g. chair rise
4
eCOA types supported: PRO, ObsRO, ClinRO, PerfO
0
minimum patient count to build and test a study
EU + US
hosting regions for multi-country rare disease programs
Free
sandbox to test the full build before enrolling patient 1
Small, scattered populations
A rare disease study rarely looks like a large Phase 3 program. It looks like a handful of specialist sites, sometimes across several countries, enrolling patients as they are identified rather than in one enrollment wave. Capture's per-site setup, QR-code enrollment and by-site data filtering work the same whether a study has 3 sites or 300.
Now recruiting
Sleep and Recovery Study
A 12-week study of sleep quality after surgery. Takes 5 minutes a day on your phone.
Check if you can take partScan to join
Print it on posters and clinic flyers
Outcomes reporting
Many rare disease populations include young children or patients who cannot reliably self-report. Capture's ePRO supports observer-reported outcomes (ObsRO) completed by a caregiver, alongside patient-reported (PRO), clinician-reported (ClinRO) and site-run performance outcomes (PerfO), all on the same platform and audit trail as the rest of the study.
Evening diary
Question 3 of 8
How would you rate your fatigue today?
0 = no fatigue, 10 = worst imaginable
Natural history and registries
The same EDC and eCRF builder power Capture's existing registry and real-world evidence (RWE) study pages; a rare disease natural history study runs on the same base.
Visit schedules with wide or irregular windows are set up the same way as any other protocol; Capture does not assume a dense, fixed visit calendar.
Capture is a data capture and export platform. Statistical design and analysis, including small-N and Bayesian approaches, are done by your own biostatistics team; see our Bayesian design guide for the current regulatory picture.
Before you switch
Free sandbox with no minimum patient or site count, so a small program is not priced like a large one.
Field-level audit trail and OTP-verified e-signatures on every record, in every hosting region.
AI drafts forms and visit schedules from a protocol or description, useful when a small team wears every hat.
Bring an existing registry or natural history dataset across during analysis; direct import depends on the source format.
Email support, typically under 24 hours, plus documentation on Enterprise.
No credit card, no minimum patient count.
There is no dedicated "rare disease" module. What it has is the same EDC, ePRO and registry support described on this page, which fits a small, scattered, caregiver-reported population well.
Yes, on the same EDC and eCRF builder as Capture's existing registry and real-world evidence study pages.
Yes. Observer-reported outcomes (ObsRO) let a caregiver complete a diary on the participant's behalf, alongside patient-, clinician- and performance-reported outcome types.
No. The free sandbox has no minimum, and the same platform works for a 3-site program or a 300-site one.
No. Capture captures and exports the data. Statistical design and analysis are your biostatistics team's work, in their own statistical software.
Yes. EU (Frankfurt) and US (N. Virginia) hosting regions, plus by-site filtering, support multi-country programs.
Yes. The free sandbox includes every feature with sample data, no credit card required.
Keep exploring
EDC for registry studies
The registry data model a rare disease study often builds on.
EDC for real-world evidence (RWE) studies
How RWD collection supports a regulatory submission.
ePRO for patient-reported outcome studies
The broader ePRO feature set behind ObsRO diaries.
Bayesian clinical trial design guide
The current FDA thinking on small-N statistical approaches.
EDC for investigator-initiated trials (IIT)
A similar fit for lean, academically-run programs.
No credit card, no minimum patient count.